JP2017516832A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017516832A5 JP2017516832A5 JP2016571196A JP2016571196A JP2017516832A5 JP 2017516832 A5 JP2017516832 A5 JP 2017516832A5 JP 2016571196 A JP2016571196 A JP 2016571196A JP 2016571196 A JP2016571196 A JP 2016571196A JP 2017516832 A5 JP2017516832 A5 JP 2017516832A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- pharmaceutical composition
- prostaglandin
- inhibitors
- formulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000694 effects Effects 0.000 claims description 3
- 229940035676 analgesics Drugs 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 239000003112 inhibitor Substances 0.000 claims 8
- 150000003180 prostaglandins Chemical class 0.000 claims 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 2
- 102000015433 Prostaglandin Receptors Human genes 0.000 claims 2
- 108010050183 Prostaglandin Receptors Proteins 0.000 claims 2
- 102100027187 Solute carrier organic anion transporter family member 2A1 Human genes 0.000 claims 2
- 101710095536 Solute carrier organic anion transporter family member 2A1 Proteins 0.000 claims 2
- 230000000202 analgesic effect Effects 0.000 claims 2
- 238000013265 extended release Methods 0.000 claims 2
- 229960001680 ibuprofen Drugs 0.000 claims 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 230000002686 anti-diuretic effect Effects 0.000 claims 1
- 230000001022 anti-muscarinic effect Effects 0.000 claims 1
- 230000002921 anti-spasmodic effect Effects 0.000 claims 1
- 229940124538 antidiuretic agent Drugs 0.000 claims 1
- 239000003160 antidiuretic agent Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 206010029446 nocturia Diseases 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000037081 physical activity Effects 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 claims 1
- 229960001475 zolpidem Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2014/041378 WO2015187183A1 (en) | 2014-06-06 | 2014-06-06 | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018204833A Division JP2019031556A (ja) | 2018-10-31 | 2018-10-31 | 排尿頻度を減少させるための医薬製剤およびその使用の方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017516832A JP2017516832A (ja) | 2017-06-22 |
| JP2017516832A5 true JP2017516832A5 (enExample) | 2017-08-03 |
Family
ID=54767122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016571196A Pending JP2017516832A (ja) | 2014-06-06 | 2014-06-06 | 排尿頻度を減少させるための医薬製剤およびその使用の方法 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3151834A4 (enExample) |
| JP (1) | JP2017516832A (enExample) |
| KR (1) | KR20170010440A (enExample) |
| CN (1) | CN106714805A (enExample) |
| AU (1) | AU2014396189A1 (enExample) |
| MX (1) | MX2016016039A (enExample) |
| RU (1) | RU2016152226A (enExample) |
| SG (1) | SG11201610383YA (enExample) |
| WO (1) | WO2015187183A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9532959B2 (en) | 2010-07-08 | 2017-01-03 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
| US10105328B2 (en) | 2014-06-06 | 2018-10-23 | Wellesley Pharmaceuticals, Llc | Composition for reducing frequency of urination, method of making and use thereof |
| EP3389661A4 (en) * | 2015-12-18 | 2019-12-18 | Wellesley Pharmaceuticals, LLC | COMPOSITION FOR REDUCING THE FREQUENCY OF URINATION, METHOD FOR THE PRODUCTION AND USE THEREOF |
| JP2019031556A (ja) * | 2018-10-31 | 2019-02-28 | ウェルズリー ファーマスーティカルズ、エルエルシー | 排尿頻度を減少させるための医薬製剤およびその使用の方法 |
| EP4096650A4 (en) * | 2020-01-30 | 2024-03-27 | The Regents of University of California | SCREENING METHOD FOR PROSTAGLANDIN E SYNTHASE 3 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010029519A (ko) * | 1996-09-19 | 2001-04-06 | 이곤 이 버그 | 요실금 치료 방법 |
| EP1447096A1 (en) * | 2001-11-19 | 2004-08-18 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary frequency |
| WO2003070233A1 (en) * | 2002-02-19 | 2003-08-28 | Pharmacia Corporation | Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence |
| US20080009538A1 (en) * | 2005-03-21 | 2008-01-10 | Phil Skolnick | Methods and compositions for the treatment of urinary incontinence |
| MY173582A (en) * | 2012-01-04 | 2020-02-04 | Wellesley Pharmaceuticals Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| BR112014016550A8 (pt) * | 2012-01-04 | 2017-07-04 | Wellesley Pharmaceuticals Llc | formulação de liberação retardada para reduzir a frequência de urinação e método de uso da mesma |
| BR112014020271A8 (pt) * | 2012-03-19 | 2017-07-11 | Wellesley Pharmaceuticals Llc | Composição farmacêutica e métodos para diminuir a frequência de micção em paciente |
-
2014
- 2014-06-06 EP EP14894044.8A patent/EP3151834A4/en not_active Ceased
- 2014-06-06 CN CN201480081004.5A patent/CN106714805A/zh active Pending
- 2014-06-06 JP JP2016571196A patent/JP2017516832A/ja active Pending
- 2014-06-06 WO PCT/US2014/041378 patent/WO2015187183A1/en not_active Ceased
- 2014-06-06 SG SG11201610383YA patent/SG11201610383YA/en unknown
- 2014-06-06 AU AU2014396189A patent/AU2014396189A1/en not_active Abandoned
- 2014-06-06 RU RU2016152226A patent/RU2016152226A/ru not_active Application Discontinuation
- 2014-06-06 MX MX2016016039A patent/MX2016016039A/es unknown
- 2014-06-06 KR KR1020177000237A patent/KR20170010440A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017516832A5 (enExample) | ||
| GEP20135919B (en) | Benzoic acid (1-phenyl-2-pyridin-4-yl) ethyl esters as phosphodiesterase inhibitors | |
| RU2019101159A (ru) | Композиции для непрерывного введения ингибиторов допа-декарбоксилазы | |
| AR122580A2 (es) | Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales | |
| WO2009066152A3 (en) | Haloallylamine inhibitors of ssao/vap-1 and uses therefor | |
| WO2017171535A8 (en) | Compositions | |
| NZ619076A (en) | Isoxazolines as inhibitors of fatty acid amide hydrolase | |
| AU2015287773A1 (en) | Modulators of toll-like receptors for the treatment of HIV | |
| JP2013509429A5 (enExample) | ||
| HRP20221304T1 (hr) | Kombinacija koja sadrži inhibitor mek i inhibitor b-raf | |
| MX352647B (es) | Metodo para temporizar una colonoscopia en donde se administra una composicion de picosulfato. | |
| MX391077B (es) | Composiciones de fenfluramina y métodos de preparación de las mismas. | |
| TN2012000435A1 (en) | Agomelatine hydrochloride hydrate and preparation thereof | |
| JP2013503110A5 (enExample) | ||
| JP2018048151A5 (enExample) | ||
| NZ734152A (en) | Compounds, compositions and methods useful for cholesterol mobilisation | |
| JP2016511753A5 (enExample) | ||
| WO2011089126A3 (en) | Novel retigabine composition | |
| MX2013014142A (es) | Composicion farmaceutica o nutraceutica de resistencia gastrica con resistencia contra la influenza de etanol. | |
| JP2013510127A5 (enExample) | ||
| JP2014533681A5 (enExample) | ||
| RU2015140572A (ru) | Способы лечения колоректального рака | |
| TW201700098A (zh) | 治療ｂ型肝炎病毒的方法 | |
| WO2012112447A3 (en) | Histone deacetylase inhibitors and methods of use thereof | |
| WO2012078470A3 (en) | Methods of small molecule directed regeneration from pluripotent stem cells |